• Ali Ayoub, Karnika Ayinapudi, Ahmed Al-Ogaili, Muhammad Siyab Panhwar, Wael Dakkak, and Thierry LeJemtel.
• Tulane University Heart and Vascular Institute, 1415 Tulane Ave, New Orleans, LA, 70112, USA. Aayoub1@tulane.edu.
• Am J Cardiovasc Drugs. 2021 Mar 1; 21 (2): 153-163.

AbstractThe optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention remains a controversial topic. The European Society of Cardiology and the American College of Cardiology/American Heart Association recommend at least 6 and 12 months of DAPT after PCI in patients with stable coronary artery disease or acute coronary syndrome, respectively. Although prolonging DAPT duration reduces ischemic events, it is associated with higher rates of bleeding and possible fatal outcomes. The DAPT score can be an important tool to identify patients who may still benefit from prolonged therapy. Nevertheless, several recent randomized controlled trials showed that shortening DAPT duration from 12 to 1-3 months reduces bleeding rates without significantly increasing ischemic event rates. These trials also suggested replacing acetylsalicylic acid (aspirin) with P2Y12 inhibitors after short-term DAPT. We review and compare past and present studies regarding DAPT and analyze the evidence favoring a short DAPT duration and the long-term single antiplatelet agent of choice.

20 keywords...

hide…